Viking Therapeutics, Inc (VKTX)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for metabolic and endocrine disorders. The company utilizes its proprietary platform to advance novel treatments targeting liver and metabolic diseases, as well as rare genetic disorders.
Company News
The article highlights three biotech stocks with significant potential growth: Viking Therapeutics, ImmunityBio, and Maze Therapeutics, each showing promising clinical trial results and analyst optimism despite current market volatility.
Eli Lilly is emerging as a leader in the weight loss drug market, with blockbuster drugs Mounjaro and Zepbound generating significant revenue. The company is developing additional weight loss treatments, including an oral pill and a potentially more effective injectable drug, positioning itself strongly in a market expected to grow to $95 billion by decade's end.
Viking Therapeutics, a clinical-stage biopharmaceutical company, will participate in multiple investor conferences in September 2025, including events by Cantor, Morgan Stanley, Bernstein, and Stifel, to discuss their ongoing research in metabolic and endocrine disorder therapies.
Viking Therapeutics, a biotech firm without any marketed drugs, is set to report its Q2 earnings. Investors will focus on updates related to its pipeline candidates, including VK2809 for NASH and VK2735 for obesity. The company's strong cash balance and robust pipeline development provide growth potential, though it faces competition in the obesity market.
Eli Lilly and Novo Nordisk have created the biggest ever pharmaceutical market with its miraculous weight loss drugs. Read more on LLY stock here.
